{"id":24852,"date":"2025-01-30T22:37:06","date_gmt":"2025-01-31T03:37:06","guid":{"rendered":"https:\/\/tienda.gsgeducation.com\/?p=24852"},"modified":"2025-03-17T05:12:54","modified_gmt":"2025-03-17T10:12:54","slug":"synthroid-levothyroxine-sodium-side-effects-uses-11","status":"publish","type":"post","link":"https:\/\/tienda.gsgeducation.com\/?p=24852","title":{"rendered":"Synthroid Levothyroxine Sodium: Side Effects, Uses, Dosage, Interactions, Warnings"},"content":{"rendered":"

Synthroid Levothyroxine Sodium: Side Effects, Uses, Dosage, Interactions, Warnings<\/h1>\n

These include urticaria, pruritus, skin rash, flushing, angioedema, various gastrointestinal symptoms (abdominal pain, nausea, vomiting and diarrhea), fever, arthralgia, serum sickness, and wheezing. Hypersensitivity to levothyroxine itself is not known to occur. For adult patients with primary hypothyroidism, titrate until the patient is clinically euthyroid and the serum TSH returns to normal see Recommended Dosage And Titration.<\/p>\n

What Drugs, Substances, or Supplements Interact with Synthroid?<\/h2>\n

Many other medicines can be affected by your thyroid hormone levels. Certain other medicines may also increase or decrease the effects of Synthroid. Addition of SYNTHROID therapy in patients with diabetes mellitus may worsen glycemic control and result in increased antidiabetic agent or synthroid caes<\/a> insulin requirements. Carefully monitor glycemic control, especially when thyroid therapy is started, changed, or discontinued see Warnings and Precautions (5.5). Do not administer in foods that decrease absorption of SYNTHROID, such as soybean-based infant formula see Drug Interactions (7.9). Monitor for cardiac arrhythmias during surgical procedures in patients with coronary artery disease receiving suppressive SYNTHROID therapy.<\/p>\n

The recommended starting daily dosage of SYNTHROID in adults with primary, secondary, or tertiary hypothyroidism is based on age and comorbid cardiac conditions, as described in Table 1. For patients at risk of atrial fibrillation or patients with underlying cardiac disease, start with a lower dosage and titrate the dosage more slowly to avoid exacerbation of cardiac symptoms. Dosage titration is based on serum TSH or free-T4 see Dosage and Administration (2.2). For secondary or tertiary hypothyroidism, serum TSH is not a reliable measure of SYNTHROID dosage adequacy and should not be used to monitor therapy. Use the serum free-T4 level to titrate SYNTHROID dosing until the patient is clinically euthyroid and the serum free-T4 level is restored to the upper half of the normal range see Dosage and Administration (2.3). Assess compliance, dose of medication administered, and method of administration prior to increasing the dose of SYNTHROID see WARNINGS AND PRECAUTIONS and Use In Specific Populations.<\/p>\n

Datas de Publica\u00e7\u00e3o<\/h3>\n

Monitor patients receiving concomitant SYNTHROID and sympathomimetic agents for signs and symptoms of coronary insufficiency. Carefully monitor glycemic control, especially when thyroid therapy is started, changed, or discontinued see WARNINGS AND PRECAUTIONS. Do not administer in foods that decrease absorption of SYNTHROID, such as soybean-based infant formula see DRUG INTERACTIONS. The signs and symptoms of overdosage are those of hyperthyroidism see Warnings and Precautions (5) and Adverse Reactions (6).<\/p>\n

Familial hyper- or hypo-thyroxine binding globulinemias have been described, with the incidence of TBG deficiency approximating 1 in 9000. Concurrent use of tyrosine-kinase inhibitors such as imatinib may cause hypothyroidism. Monitor serum free-T4 levels and maintain in the upper half of the normal range in these patients. The recommended daily dosage of SYNTHROID in pregnant patients is described in Table 3. Start at a lower starting dosage and increase the dosage every 4 to 6 weeks as needed based on clinical and laboratory response. If so, advise them to stop biotin supplementation at least 2 days before assessing TSH and\/or T4 levels see DOSAGE AND ADMINISTRATION and DRUG INTERACTIONS.<\/p>\n

Absorption of orally administered T4 from the gastrointestinal tract ranges from 40% to 80%. The majority of the SYNTHROID dose is absorbed from the jejunum and upper ileum. The relative bioavailability of SYNTHROID tablets, compared to an equal nominal dose of oral levothyroxine sodium solution, is approximately 93%. T4 absorption is increased by fasting, and decreased in malabsorption syndromes and by certain foods such as soybeans. In addition, many drugs and foods affect T4 absorption see Drug Interactions (7). In addition, many drugs and foods affect T4 absorption see DRUG INTERACTIONS.<\/p>\n